LINC01609

Across TCGA pan-cancer cohorts, LINC01609 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated LINC01609 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC01609 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01609 expression acts as an unfavorable survival marker.

LIHC, LUSC, and ESCA are the cancer types where LINC01609 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.588	0.787	.006	69	view →
LUSC	DFS	Tertile	III,IV	0.010	0.754	<.001	54	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
SKCM	OS	Tertile	III,IV	0.129	0.408	.010	33	view →
STAD	DFS	Tertile	All	0.523	0.734	.013	27	view →
GBM	DFS	Tertile	All	0.048	0.257	.001	18	view →
UCEC	DFS	Tertile	IV	0.206	0.704	.033	18	view →
KICH	DFS	Tertile	II,III,IV	0.228	0.809	.001	15	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LINC01609–LIHC (OS)

Open the LIHC breakdown →